Pulmonary surfactant associated protein B
Showing 1 - 25 of >10,000
Lung Diseases, Respiratory Distress Syndrome, Newborn, Pulmonary Surfactant Trial in Saint Louis
Recruiting
- Lung Diseases
- +3 more
-
Saint Louis, MissouriWashington University School of Medicine
Nov 22, 2022
Chronic Lung Disease of Prematurity, Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia Trial
Not yet recruiting
- Chronic Lung Disease of Prematurity
- +2 more
- Recombinant fragment of human surfactant protein D (rfhSP-D)
- (no location specified)
Jun 6, 2023
Tumors Malignant Trial in Shanghai (B1962)
Not yet recruiting
- Neoplasms Malignant
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Dec 13, 2022
Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between
Not yet recruiting
- Recurrent ALK Positive Large B-Cell Lymphoma
- +28 more
- Biospecimen Collection
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 17, 2022
Genetic Regulation of Surfactant Deficiency
Completed
- Respiratory Distress Syndrome, Newborn
-
Saint Louis, MissouriSt. Louis Children's Hospital
Jun 4, 2021
Surfactant Dysfunction Trial in Shanghai (Hydroxychloroquin)
Recruiting
- Surfactant Dysfunction
-
Shanghai, Shanghai, ChinaChildren's hospital of Fudan University
Mar 14, 2022
RDS of Prematurity, Surfactant Protein B Deficiency, Chronic Lung Disease Trial in United States (surfactant airway device)
Unknown status
- RDS of Prematurity
- +2 more
- surfactant airway device
-
San Diego, California
- +3 more
Oct 21, 2020
Danon Disease Trial in La Jolla, Aurora, Philadelphia (RP-A501)
Recruiting
- Danon Disease
- RP-A501
-
La Jolla, California
- +2 more
Aug 24, 2021
Connective Tissue Diseases, Thrombocytopenia Trial in China (Telitacicept, Placebo)
Not yet recruiting
- Connective Tissue Diseases
- Thrombocytopenia
- Telitacicept
- Placebo
-
Hefei, Anhui, China
- +21 more
Aug 18, 2023
Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited Trial in India, United States (Oral Ifetroban, Oral Placebo)
Recruiting
- Scleroderma, Diffuse
- +7 more
- Oral Ifetroban
- Oral Placebo
-
Tucson, Arizona
- +15 more
Jun 30, 2022
HIV/AIDS, Tuberculosis, Pulmonary Trial in Durban (Biktarvy®, TLD- fixed-drug combination single tablet)
Recruiting
- HIV/AIDS
- Tuberculosis, Pulmonary
- Biktarvy®
- TLD- fixed-drug combination single tablet
-
Durban, KwaZulu-Natal, South AfricaCAPRISA Springfield Clinical Research Site
Mar 14, 2022
Pulmonary Interstitial Emphysema in ARDS (PIE-ARDS)
Not yet recruiting
- Acute Respiratory Distress Syndrome
- Barotrauma
- Blood and bronchoalveolar fluid collection and analysis
- Chest CT scan
-
Cagliari, Italy
- +3 more
Aug 17, 2023
COVID-19 Respiratory Outcomes Registry
Active, not recruiting
- Covid19
- Questionnaires and Patient Reported Outcomes (PROs)
- +10 more
-
Saint Louis, Missouri
- +3 more
Oct 11, 2022
Advanced Malignant Solid Tumor, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial
Recruiting
- Advanced Malignant Solid Neoplasm
- +8 more
- Imatinib Mesylate
- Ipilimumab
-
Houston, TexasM D Anderson Cancer Center
Aug 1, 2022
Respiratory Distress Syndrome in Premature Infant Trial (Surfactant administration following lung mechanics assessment in
Not yet recruiting
- Respiratory Distress Syndrome in Premature Infant
- Surfactant administration following lung mechanics assessment in addition to clinical assessment
- Surfactant administration following clinical assessment
- (no location specified)
Mar 28, 2023
Respiratory Distress Syndrome, Newborn Trial in United States (CHF5633, Poractant alfa)
Completed
- Respiratory Distress Syndrome, Newborn
- CHF5633
- Poractant alfa
-
Mobile, Alabama
- +22 more
Jul 19, 2021
Bronchopulmonary Dysplasia, Chronic Pulmonary Insufficiency of Prematurity Trial in Roma (Poractant Alfa Intratracheal
Recruiting
- Bronchopulmonary Dysplasia
- Chronic Pulmonary Insufficiency of Prematurity
- Poractant Alfa Intratracheal Suspension [Curosurf]
-
Roma, ItalyFondazione Policlinico Agostino Gemelli IRCCS
Dec 4, 2021
Respiratory Tract Diseases Trial (intratracheal administration of surfactant/budesonide, incidence of bronchopulmonary
Not yet recruiting
- Respiratory Tract Diseases
- intratracheal administration of surfactant/budesonide
- incidence of bronchopulmonary dysplasia
- (no location specified)
Sep 9, 2022
Type 2 Diabetes Trial in Spain (liraglutide, )
Respiratory Distress Syndrome, Bronchopulmonary Dysplasia Trial in Roma (Ventilator for High-frequency Oscillatory Ventilation
Recruiting
- Respiratory Distress Syndrome
- Bronchopulmonary Dysplasia
- Ventilator for High-frequency Oscillatory Ventilation (HFOV)
- Less invasive surfactant administration (LISA)
-
Roma, ItalyFondazione Policlinico Agostino Gemelli IRCCS
Jan 25, 2023
Interstitial Lung Disease, Surfactant Dysfunction Trial in Shanghai (Hydroxychloroquine)
Not yet recruiting
- Interstitial Lung Disease
- Surfactant Dysfunction
-
Shanghai, Shanghai, ChinaChildren's hospital of Fudan University
Jan 9, 2023
Respiratory Distress Syndrome, Newborn Trial in Detroit (Surfactant)
Completed
- Respiratory Distress Syndrome, Newborn
-
Detroit, MichiganHutzel Women's Hospital
Jul 30, 2021
Diabetes, Type 2, Preterm Birth, Pregnancy, High Risk Trial in Birmingham (Sliding Scale Insulin, Up-Titration of Home Insulin,
Recruiting
- Diabetes Mellitus, Type 2
- +3 more
- Sliding Scale Insulin
- +3 more
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Dec 7, 2022
Danon Disease Trial in La Jolla, Philadelphia (RP-A501)
Recruiting
- Danon Disease
- RP-A501
-
La Jolla, California
- +1 more
Oct 17, 2023
Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity Trial in Tucson (Infants in the study group
Recruiting
- Infant, Extremely Premature
- +3 more
- Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
- Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
-
Tucson, ArizonaUniversity of Arizona
Oct 31, 2022